Melanóma: vizsgálatok itt: Kína
70 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 2. fázisTaking peoplePhase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 15
- Run by
- Tianjin Medical University Second Hospital
See details and how to joinNCT07170293 - 1/2. fázisTaking peopleAMT-253 in Patients With Advanced Solid Tumours
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 96
- Run by
- Multitude Therapeutics Inc.
See details and how to joinNCT06209580 - 1. fázisTaking peopleAn Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 15
- Run by
- Guangzhou FineImmune Biotechnology Co., LTD.
See details and how to joinNCT06942143 - 3. fázisTaking peopleOH2 Injection in Melanoma
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Ürümqi, Weifang, Wuhan, Xi’an, Zhengzhou
- Életkor
- 18 év and over
- People
- 340
- Run by
- Binhui Biopharmaceutical Co., Ltd.
See details and how to joinNCT05868707 - 1/2. fázisTaking peopleOH2 Injection in Combination With HX008 for Melanoma.
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Binhui Biopharmaceutical Co., Ltd.
See details and how to joinNCT04616443 - 4. fázisNot yet taking people in KínaEfficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study
- Where
- Shijiazhuang
- Életkor
- 18 év and over
- People
- 40
- Run by
- Hebei Medical University Fourth Hospital
See details and how to joinNCT07004335 - 2. fázisTaking peoplePerioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 58
- Run by
- Fudan University
See details and how to joinNCT06965231 - 1/2. fázisTaking peopleFluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 50
- Run by
- Jun Guo
See details and how to joinNCT05983237 - 2. fázisTaking peopleCamrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT05512481 - 2. fázisNot yet taking people in KínaClinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer
- Where
- Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 20
- Run by
- YongZhang
See details and how to joinNCT06670300 - 2. fázisNot yet taking people in KínaTQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
- Where
- Beijing, Changchun, Changsha, Hangzhou, Jinan, Shanghai, Taiyuan, Tianjin, Ürümqi, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 54
- Run by
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT06500091 - 3. fázisTaking peopleComparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 165
- Run by
- Shanghai Kechow Pharma, Inc.
See details and how to joinNCT06008106 - 2/3. fázisTaking peopleTrans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
- Where
- Guanzhou
- Életkor
- 18 év and over
- People
- 200
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03755739 - No phaseTaking peopleMicroecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
- Where
- Beijing
- Életkor
- 18 év to 100 év
- People
- 50
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT06203249 - 2. fázisNot yet taking people in KínaCVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 98
- Run by
- Convalife (Shanghai) Co., Ltd.
See details and how to joinNCT06183736 - 3. fázisTaking peopleCamrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 140
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT05789043 - 1/2. fázisNot yet taking people in KínaInterferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
- Where
- Xi'an
- Életkor
- 18 év to 75 év
- People
- 48
- Run by
- Xijing Hospital
See details and how to joinNCT05539118 - 1. fázisTaking peopleA Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 15
- Run by
- Suzhou BlueHorse Therapeutics Co., Ltd.
See details and how to joinNCT05366478 - 2. fázisTaking peopleNeoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma
- Where
- Changchun
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- Di Wu
See details and how to joinNCT04331093 - 2. fázisNot yet taking people in KínaLenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 26
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT04622566